Jacob Johnson
Stock Analyst at Stephens & Co.
(2.90)
# 1,735
Out of 5,030 analysts
75
Total ratings
45.76%
Success rate
9.46%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $240.21 | -0.09% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $8.55 | -29.82% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $6.47 | -7.19% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $30.97 | +93.74% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $209.06 | +50.67% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $538.92 | +26.18% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $152.60 | +11.40% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $5.11 | -2.15% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.61 | +583.23% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $24.44 | +55.48% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $10.12 | +67.98% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.53 | +63.40% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $61.86 | +40.64% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $270.60 | +44.12% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $10.05 | +79.10% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.68 | +124.30% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $27.32 | +6.15% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $178.52 | +111.18% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $240.21
Upside: -0.09%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $8.55
Upside: -29.82%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $6.47
Upside: -7.19%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $30.97
Upside: +93.74%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $209.06
Upside: +50.67%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $538.92
Upside: +26.18%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $152.60
Upside: +11.40%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $5.11
Upside: -2.15%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.61
Upside: +583.23%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $24.44
Upside: +55.48%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $10.12
Upside: +67.98%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.53
Upside: +63.40%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $61.86
Upside: +40.64%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $270.60
Upside: +44.12%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $10.05
Upside: +79.10%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.68
Upside: +124.30%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $27.32
Upside: +6.15%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $178.52
Upside: +111.18%